结直肠癌(colorectal cancer, CRC) 是全球最常见的消化系统恶性肿瘤, 因早期诊断率低,
多数患者初诊时已处于进展期, 预后极差. 单用免疫检查点抑制剂(immune checkpoint …

在过去10 余年, 尽管晚期结直肠癌(colorectal cancer, CRC) 的总生存率得到明显改善,
但晚期CRC 仍然是全球恶性肿瘤死亡的主要原因之一. 化疗和生物治疗是目前主要治疗策略 …

结直肠癌(colorectal cancer, CRC) 是我国乃至全世界常见的恶性肿瘤, 转移事件发生率高.
免疫治疗在转移性结直肠癌(metastatic CRC, mCRC) 的治疗中作为一种新兴的治疗方法 …

Colorectal cancer (CRC) is one of the most common malignant tumours of the digestive
system, and most patients are already in an advanced stage at the time of diagnosis …

Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically
been notable worldwide and many attempts have been made to raise the overall survival of …

Aim: PD-1 inhibitors have a leading role among immunotherapy while its efficacy on
colorectal cancer (CRC) patients did not reach consensus and the small sample size …

At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer,
melanoma, bladder cancer and other tumor species, and its treatment methods are also …

Colorectal cancer (CRC) is a common malignancy with a high incidence of metastatic events
in China and the world. Immunotherapy has received increasing attention as an emerging …

Although the overall survival rate of colorectal cancer has been significantly improved over
the last decade, advanced colorectal cancer remains one of the main causes of death from …

结直肠癌是全球最常见的恶性肿瘤之j, 大部分患者诊断时己发生转移, 其预后较差.
近年来免疫检查点抑制剂在多种恶性肿瘤治疗方面取得了突破性进展, 是目前的研究热点之j …